In this edition of CRA Insights: Intellectual Property, consultants with CRA’s Intellectual Property Practice discuss three recent cases concerning IP damages.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...